Loading...
Glimepride 2mg + Metformin 500mg (Sr) + Pioglitazone 15 mg
A triple-action oral antidiabetic formulation developed for comprehensive management of type 2 diabetes mellitus. STELTOG-GP2 combines glimepiride, sustained-release metformin, and pioglitazone to improve insulin secretion, reduce hepatic glucose production, and enhance peripheral insulin sensitivit.
A triple-action oral antidiabetic formulation developed for comprehensive management of type 2 diabetes mellitus. STELTOG-GP2 combines glimepiride, sustained-release metformin, and pioglitazone to improve insulin secretion, reduce hepatic glucose production, and enhance peripheral insulin sensitivity for effective long-term glycemic control.
Contains Glimepiride (a sulfonylurea), Metformin SR (a biguanide), and Pioglitazone (a thiazolidinedione), providing a multi-mechanism approach to control blood glucose levels when monotherapy or dual therapy is insufficient.
Glimepiride stimulates pancreatic β-cells to release insulin, helping reduce elevated blood glucose levels, particularly after meals.
Metformin lowers glucose production in the liver, reduces intestinal glucose absorption, and improves peripheral glucose uptake, contributing t...
Product descriptions, dosage forms, and compositions listed on the website are for reference by licensed practitioners and distributors only.
